Transcend Capital Advisors’s Regeneron Pharmaceuticals REGN Stock Holding History

Transcend Capital Advisors’s Portfolio REGN Stock Details REGN Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q1	$793K	Buy	1,026 +51	+5%	+$39K	0.06%	283
2025 Q4	$753K	Buy	975 +296	+44%	+$201K	0.06%	285
2025 Q3	$382K	Buy	+679	New	+$384K	0.03%	451
2023 Q1	–	Sell	-418	Closed	-$302K	–	516
2022 Q4	$302K	Buy	418 +114	+38%	+$84.1K	0.03%	361
2022 Q3	$209K	Buy	+304	New	+$191K	0.02%	439
2020 Q2	–	Sell	-467	Closed	-$239K	–	179
2020 Q1	$239K	Buy	+467	New	+$193K	0.07%	180

Other funds holding REGN

BlackRock New York $5.72T AUM 30.48% 1-Year Est. Return

VCM

Vanguard Capital Management Malvern, Pennsylvania $4.04T AUM

State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return

Dodge & Cox San Francisco, California $182B AUM 14.68% 1-Year Est. Return

JP Morgan Chase New York $1.56T AUM 27.86% 1-Year Est. Return

Invesco Atlanta, Georgia $1.02T AUM 30.18% 1-Year Est. Return

Franklin Resources San Mateo, California $408B AUM 30.18% 1-Year Est. Return

Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return

T. Rowe Price Associates Baltimore, Maryland $865B AUM 30.76% 1-Year Est. Return

Nuveen Charlotte, North Carolina $369B AUM 31.66% 1-Year Est. Return

Transcend Capital Advisors's REGN Position: Q1 2026 in Review

Transcend Capital Advisors increased its Regeneron Pharmaceuticals (REGN) stake by 5.2% in Q1 2026, buying an estimated $39K and bringing the position to 1,026 shares worth $793K. The position accounts for 0.06% of the portfolio, ranked #283.

Transcend Capital Advisors first reported a position in REGN in Q1 2020 and has held it in 6 quarters since. 1,392 funds tracked by Wall St. Rank hold REGN as of Q1 2026.

Transcend Capital Advisors held 1,026 shares of Regeneron Pharmaceuticals worth $793K as of Q1 2026.
Transcend Capital Advisors bought 51 Regeneron Pharmaceuticals shares in Q1 2026, an estimated $39K.
Regeneron Pharmaceuticals made up 0.06% of Transcend Capital Advisors's portfolio in Q1 2026, its #283 holding.
Transcend Capital Advisors first reported a position in Regeneron Pharmaceuticals in Q1 2020 and has held it in 6 quarters since.
1,392 funds tracked by Wall St. Rank held Regeneron Pharmaceuticals as of Q1 2026.

Based on Transcend Capital Advisors's 13F filing for Q1 2026, filed 13 May 2026.